Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.
Alexander T SandhuPaul A HeidenreichJohn K LinJustin ParizoJay BhattacharyaJeremy D Goldhaber-FiebertPublished in: Circulation. Cardiovascular quality and outcomes (2022)
The development of accurate prospective estimates of treatment effectiveness using actual enrollee characteristics will be critical for successful PLR. If able to meet these requirements, PLRs could incentivize insurers to expand access to expensive treatments by reducing financial risk.